Introduction

Optilume benign prostatic hyperplasia(BPH) is a novel treatment which uses a combination of urethral dilation and paclitaxel delivery to maintain long-term patency. The EVEREST-I study evaluates its effectiveness in improving urine flow and reducing lower urinary tract symptoms (LUTS). 

Materials and Methods

Out of the 80 subjects enrolled, 53 completed the 5-year follow-up and the subjects receiving alternative therapy for BPH were discontinued from further follow-up. International Prostate Symptom Score (IPSS) and BPH Impact Index (BPH-II), functional improvement measured by peak urinary flow rate (Qmax) and post-void residual volume (PVR) were to identify symptom improvement. 

Results

The IPSS improved on an average of 10.6 points from the baseline, other metrics like QoL, BPH-II also showed steady improvement.  The functional improvement was also maintained with an average baseline Qmax of 10.9 mL/sec which increased to 17.8mL/sec after the 5-year follow up.

Conclusion

It was concluded that treatment with Optilume BPH resulted in sustained, symptomatic and functional improvements which were maintained with limited rates of re-treatment: 1 surgical retreatment (1.3%) and 2 patients re-initiating BPH medications (2.5%). Therefore, Optilume BPH is an effective and a durable option for treatment of secondary LUTS.

European Association of Urology, 21-24 March 2025, Madrid, Spain